Peptide profile
KPV-cyclo (cyclo-KPV)
Cyclized KPV for IBD and gut inflammation
Compare KPV-cyclo (cyclo-KPV) with other peptides →Summary
Cyclized KPV analog for enhanced gut stability.
- Typical dose
- 100-300mcg oral or 50-100mcg injectable 2x daily
- Route
- Subcutaneous, Oral
- Cycle length
- 30-60 days
- Evidence
- Anecdotal
Mechanism
How it works
Cyclo-KPV is like a locked version of KPV — the cyclization acts like a seatbelt that prevents enzymes from breaking it down until it reaches its target.
Cyclo-KPV is a chemically cyclized form of KPV that resists enzymatic degradation in the GI tract, increasing bioavailability for systemic anti-inflammatory effects.
Reported in research
Benefits
- More stable than linear KPV in gut
- Potent anti-inflammatory for IBD
- Reduces TNF-α, IL-6, and IL-1β
- May treat Crohn's and ulcerative colitis
Context, not a prescription
Dosing
- Typical range
- 100-300mcg oral or 50-100mcg injectable 2x daily (Subcutaneous, Oral)
- Cycle length
- 30-60 days
Safety
Side effects & contraindications
Possible side effects
- Mild injection site irritation
- Nausea
- Headache
Contraindications
- Pregnancy or breastfeeding
- Autoimmune disease flare
Research information, not medical advice. Always consult a licensed clinician before considering any peptide.
In depth
Full profile
What it does
Reduced gut inflammation, less diarrhea and abdominal pain.
How it works
Cyclo-KPV is like a locked version of KPV — the cyclization acts like a seatbelt that prevents enzymes from breaking it down until it reaches its target.
Binds to melanocortin receptors (MC1R, MC3R) on immune cells in gut-associated lymphoid tissue, reducing NF-κB activation.
What to expect
Anti-inflammatory effects within 2-3 weeks.
- Weeks 1-2: Reduced frequency of bowel movements.
- Weeks 3-4: Less abdominal pain and urgency.
- Weeks 6-8: Calprotecin reduction (inflammation biomarker).
Good to know
- Start with lower dose
- Monitor for worsening GI symptoms
Staying safe
- Mild injection site irritation
Avoid if you have:
- Pregnancy or breastfeeding
- Autoimmune disease flare
Mechanism of action
Cyclo-KPV is a chemically cyclized form of KPV that resists enzymatic degradation in the GI tract, increasing bioavailability for systemic anti-inflammatory effects.
Binds to melanocortin receptors (MC1R, MC3R) on immune cells in gut-associated lymphoid tissue, reducing NF-κB activation.
Pharmacodynamics
Anti-inflammatory effects within 2-3 weeks.
Reduced gut inflammation, less diarrhea and abdominal pain.
Timeline
- Weeks 1-2: Reduced frequency of bowel movements.
- Weeks 3-4: Less abdominal pain and urgency.
- Weeks 6-8: Calprotecin reduction (inflammation biomarker).
Comparisons
- Cyclo-KPV — effectiveness Emerging, safety Emerging, cost $$, Medium to use
- BPC-157 — effectiveness Moderate, safety Good, cost $$, Easy to use
Adverse effects
Common:
- Mild injection site irritation
Rare:
- Nausea
- Headache
Contraindications & risk mitigation
Contraindicated in:
- Pregnancy or breastfeeding
- Autoimmune disease flare
- Start with lower dose
- Monitor for worsening GI symptoms
Qué hace
Reducción de la inflamación intestinal, menos diarrea y dolor abdominal.
Cómo funciona
Cyclo-KPV es como una versión bloqueada de KPV: la ciclación actúa como un cinturón de seguridad que impide que las enzimas lo degraden hasta que alcanza su objetivo.
Se une a los receptores de melanocortina (MC1R, MC3R) en células inmunitarias del tejido linfoide asociado al intestino, reduciendo la activación de NF-κB.
Qué esperar
Efectos antiinflamatorios en 2-3 semanas.
- Semanas 1-2: Reducción en la frecuencia de deposiciones.
- Semanas 3-4: Menos dolor abdominal y urgencia.
- Semanas 6-8: Reducción de calprotectina (biomarcador de inflamación).
Bueno saber
- Comenzar con una dosis menor
- Vigilar el empeoramiento de síntomas gastrointestinales
Manteniéndose seguro
- Irritación leve en el sitio de inyección
Evitar si tienes:
- Embarazo o lactancia
- Crisis de enfermedad autoinmune
Mecanismo de acción
Cyclo-KPV es una forma químicamente ciclada de KPV que resiste la degradación enzimática en el tracto gastrointestinal, aumentando la biodisponibilidad para efectos antiinflamatorios sistémicos.
Se une a los receptores de melanocortina (MC1R, MC3R) en células inmunitarias del tejido linfoide asociado al intestino, reduciendo la activación de NF-κB.
Farmacodinamia
Efectos antiinflamatorios en 2-3 semanas.
Reducción de la inflamación intestinal, menos diarrea y dolor abdominal.
Cronología
- Semanas 1-2: Reducción en la frecuencia de deposiciones.
- Semanas 3-4: Menos dolor abdominal y urgencia.
- Semanas 6-8: Reducción de calprotectina (biomarcador de inflamación).
Comparaciones
- Cyclo-KPV — efectividad Emergente, seguridad Emergente, costo $$, Media de usar
- BPC-157 — efectividad Moderada, seguridad Buena, costo $$, Fácil de usar
Efectos adversos
Comunes:
- Irritación leve en el sitio de inyección
Raros:
- Náuseas
- Dolor de cabeza
Contraindicaciones y mitigación de riesgos
Contraindicado en:
- Embarazo o lactancia
- Crisis de enfermedad autoinmune
- Comenzar con una dosis menor
- Vigilar el empeoramiento de síntomas gastrointestinales
Reference data
Specifications
- Route
- Subcutaneous, Oral
- Cycle length
- 30-60 days
FAQ
Common questions
Is cyclo-KPV better than KPV?
More stable in gut for oral use; injectable KPV is still effective.
Can it put Crohn's into remission?
Animal studies promising; human data currently limited.
What is the evidence level?
This compound is classified as Anecdotal. Evidence relies primarily on self-reported user experiences. Controlled studies are lacking.
Research
Research & sources
Current evidence for KPV-cyclo (cyclo-KPV) is rated as Anecdotal. No controlled clinical research is available.
- 1. Cyclized KPV in IBD (2018) — DOI:10.1016/j.ejmech.2018.07.056
- 2. Cyclic peptides gut stability (2019) — DOI:10.1021/acs.chemrev.8b00804
- 3. Cyclized KPV in IBD (2018)
- 4. Cyclic peptides gut stability (2019)